SEHK:1696

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Sisram Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1696 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: 1696's weekly volatility has increased from 10% to 17% over the past year.


Market Performance


7 Day Return

66.0%

1696

11.2%

HK Medical Equipment

3.6%

HK Market


1 Year Return

22.0%

1696

115.1%

HK Medical Equipment

15.8%

HK Market

Return vs Industry: 1696 underperformed the Hong Kong Medical Equipment industry which returned 115.1% over the past year.

Return vs Market: 1696 exceeded the Hong Kong Market which returned 15.8% over the past year.


Shareholder returns

1696IndustryMarket
7 Day66.0%11.2%3.6%
30 Day47.2%14.6%12.7%
90 Day101.2%21.5%18.3%
1 Year27.4%22.0%118.5%115.1%20.4%15.8%
3 Year-23.7%-28.8%221.3%206.1%-4.5%-14.6%
5 Yearn/a350.2%312.8%66.1%37.9%

Long-Term Price Volatility Vs. Market

How volatile is Sisram Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sisram Medical undervalued compared to its fair value and its price relative to the market?

21.5x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1696 (HK$4.93) is trading above our estimate of fair value (HK$2)

Significantly Below Fair Value: 1696 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1696 is good value based on its PE Ratio (21.5x) compared to the HK Medical Equipment industry average (30x).

PE vs Market: 1696 is poor value based on its PE Ratio (21.5x) compared to the Hong Kong market (11.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1696's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1696 is good value based on its PB Ratio (0.9x) compared to the HK Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Sisram Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sisram Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sisram Medical performed over the past 5 years?

21.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1696 has high quality earnings.

Growing Profit Margin: 1696's current net profit margins (8.2%) are lower than last year (14.7%).


Past Earnings Growth Analysis

Earnings Trend: 1696's earnings have grown significantly by 21.3% per year over the past 5 years.

Accelerating Growth: 1696's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1696 had negative earnings growth (-45%) over the past year, making it difficult to compare to the Medical Equipment industry average (17.7%).


Return on Equity

High ROE: 1696's Return on Equity (4.2%) is considered low.


Next Steps

Financial Health

How is Sisram Medical's financial position?


Financial Position Analysis

Short Term Liabilities: 1696's short term assets ($191.4M) exceed its short term liabilities ($44.5M).

Long Term Liabilities: 1696's short term assets ($191.4M) exceed its long term liabilities ($18.1M).


Debt to Equity History and Analysis

Debt Level: 1696's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: 1696's debt to equity ratio has reduced from 686.1% to 0.3% over the past 5 years.

Debt Coverage: 1696's debt is well covered by operating cash flow (1110.2%).

Interest Coverage: 1696 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Sisram Medical current dividend yield, its reliability and sustainability?

2.23%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1696's dividend (2.23%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.08%).

High Dividend: 1696's dividend (2.23%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.55%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 1696 has been paying a dividend for less than 10 years.

Growing Dividend: 1696's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (47.3%), 1696's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Lior Dayan (50 yo)

3.58yrs

Tenure

US$759,000

Compensation

Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and is responsible for its overall and day-to-day management and development. Mr. Dayan...


CEO Compensation Analysis

Compensation vs Market: Lior's total compensation ($USD759.00K) is above average for companies of similar size in the Hong Kong market ($USD304.46K).

Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Lior Dayan
CEO & Executive Director3.58yrsUS$759.00k0.026%
$ 559.6k
Liu Yi
Executive Chairman4.75yrsno datano data
Guojun Bu
CFO & Executive Director2yrsno datano data
Ran Ezioni
Chief Operating Officer2.75yrsno datano data
Avraham Farbstein
Chief Strategy Officer2.83yrsno datano data
Mei Ha Kam
Company Secretary1.08yrsno datano data

2.8yrs

Average Tenure

51yo

Average Age

Experienced Management: 1696's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lior Dayan
CEO & Executive Director3.58yrsUS$759.00k0.026%
$ 559.6k
Liu Yi
Executive Chairman4.75yrsno datano data
Guojun Bu
CFO & Executive Director2yrsno datano data
Heung Fong
Independent Non-Executive Director3.42yrsUS$25.00kno data
Yifang Wu
Non-Executive Director4.25yrsno datano data
Yao Wang
Non-Executive Director4.75yrsno datano data
Chan Chi Fung
Independent Non-Executive Director3.42yrsUS$25.00kno data
Jenny Chen
Independent Non-Executive Director3.42yrsUS$25.00kno data
Kai Yu Liu
Independent Non-Executive Director3.42yrsUS$25.00kno data
Dai Kun
Non-Executive Director1.42yrsno datano data
Rongli Feng
Non-Executive Director0.42yrno datano data

3.4yrs

Average Tenure

44yo

Average Age

Experienced Board: 1696's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sisram Medical Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sisram Medical Ltd
  • Ticker: 1696
  • Exchange: SEHK
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: HK$2.180b
  • Shares outstanding: 442.16m
  • Website: https://www.sisram-medical.com

Number of Employees


Location

  • Sisram Medical Ltd
  • 14 Halamish Street
  • Caesarea Industrial Park
  • Caesarea
  • 38900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1696SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDSep 2017

Biography

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North Amer...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/24 10:21
End of Day Share Price2021/01/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.